Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai